Acid ceramidase is upregulated in AML and represents a novel therapeutic target

There is an urgent unmet need for new therapeutics in acute myeloid leukemia (AML) as standard therapy has not changed in the past three decades and outcome remains poor for most patients. Sphingolipid dysregulation through decreased ceramide levels and elevated sphingosine 1-phosphate (S1P) promote...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Su-Fern, Liu, Xin, Fox, Todd E., Barth, Brian M., Sharma, Arati, Turner, Stephen D., Awwad, Andy, Dewey, Alden, Doi, Kenichiro, Spitzer, Barbara, Shah, Mithun Vinod, Morad, Samy A.F., Desai, Dhimant, Amin, Shantu, Zhu, Junjia, Liao, Jason, Yun, Jong, Kester, Mark, Claxton, David F., Wang, Hong-Gang, Cabot, Myles C., Schuchman, Edward H., Levine, Ross L., Feith, David J., Loughran, Thomas P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347763/
https://www.ncbi.nlm.nih.gov/pubmed/27825124
http://dx.doi.org/10.18632/oncotarget.13079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347763/
https://www.ncbi.nlm.nih.gov/pubmed/27825124
http://dx.doi.org/10.18632/oncotarget.13079

Ejemplares similares